Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birch pollen-galactomannan conjugate immunotherapy for pollen-food allergy syndrome
jRCTs031230008Completed
- Sponsor
- Japanese Society of Allergology
- Start
- May 2023
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of birch pollen-galactomannan conjugate in Pollen Food Allergy Syndrome (PFAS), sponsored by Japanese Society of Allergology. Primary endpoints: Raw apple oral challenge intake threshold, VAS score (mm) and 2 more. Started May 2023; status: completed.
02
Drugs
birch pollen-galactomannan conjugate
03
Conditions
Pollen Food Allergy Syndrome (PFAS)
Beyond the preview
Go deeper on jRCTs031230008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230008.